Utmvec myometrial uterine microvascular cell systems
Clonetics™ Myometrial Uterine Microvascular Cell Systems UtMVEC
Introduction Performance
Clonetics Myometrial Uterine Microvascular Cell Systems contain normal human myometrial uterine
microvascular endothelial cells (UtMVEC-Myo) and
optimized media for their growth. Each System can
Typical time from subculture to confluent
quickly generate UtMVEC-Myo cultures for
experimental applications in estradiol pharmacology,
gene expression, myometrial drug effects and
enzymology and uterine pathology. Clonetics
Myometrial Uterine Microvascular Cell Systems are
convenient and easy to use, allowing the researcher to focus on results. Cryopreserved UtMVEC-Myo
Quality Control
All cells are performance assayed and test negative
Proliferating UtMVEC-Myo are shipped in third or
for HIV-1, mycoplasma, hepatitis-B, hepatitis-C,
bacteria, yeast and fungi. Cell viability, morphology
Clonetics cells, medium and reagents are quality
and proliferative capacity are measured after
tested together and guaranteed to give optimum
recovery from cryopreservation. Clonetics media
performance as a complete “cell system”.
are formulated for optimal growth of specific types of
normal human cells. Each lot of medium is tested for the support of cell viability and proliferative
Cell System Components
capacity. Certificates of Analysis (CA) for each cell
• One Myometrial Uterine Microvascular Cell
strain are shipped with each order. CA for all other
Product (Cryopreserved or Proliferating)
• One Endothelial Cell Medium BulletKit® - 500 ml
Ordering Information
contains one 500 ml bottle of Endothelial Cell
Hydrocortisone, 0.5 ml; FBS, 25 ml; GA-1000,
UtMVEC-Myo, Myometrial T-25 Flask Uterine Microvascular
contains one 500 ml bottle of Endothelial Cell
Basal Medium-2 and the following growth supplements: hEGF, Hydrocortisone, GA-1000,
FBS, VEGF, hFGF-B, R3-IGF-1, Ascorbic Acid
One ReagentPack™ (CC-5034), Containing:
Characterization of Cells
Routine characterization of UtMVEC-Myo includes
immunofluorescent staining. Cells stain positive for von Willebrand's (Factor VIII) antigen and for uptake
of acetylated LDL. Cells stain negative for smooth
Cambrex Bio Science Walkersville, Inc. www.cambrex.com/bioproducts biotechserv@cambrex.com
Orders: 800-638-8174 Technical Service: 800-521-0390 Copyright 2002 Cambrex Bio Science Walkersville, Inc.
When placing an order or for technical service,
descriptions listed above. For a complete listing of all Clonetics products, refer to the Cambrex website
or the current Cambrex catalog. To obtain a
catalog, additional information or technical service
Product Warranty
CULTURES HAVE A FINITE LIFESPAN IN VITRO.
Cambrex warrants its cells only if Clonetics media
are used, and the recommended protocols are
followed. Cryopreserved UtMVEC cells are assured
to be viable and functional when thawed and
THESE PRODUCTS ARE FOR RESEARCH USE ONLY. Not
approved for human or veterinary use, for application to humans
or animals, or for use in vitro diagnostic or clinical procedures.
WARNING: CLONETICS AND POIETICS PRODUCTS CONTAIN HUMAN SOURCE MATERIAL, TREAT AS POTENTIALLY INFECTIOUS. Each cell donor, where possible, is tested by an FDA approved method and found non-reactive for
antibodies to HIV -I and hepatitis-B & C. Where donor testing is not possible, individual cell strains are tested for the presence of viral DNA from HIV -I and hepatitis-B & C by PCR. No known test method can offer complete assurance the viruses that cause HIV -I and hepatitis-B & C are absent. All human based products should be handled at BSL-2 levels (Biosafety Level 2) or higher as recommended for any human sourced material as recommended in the CDC-NIH Manual, “Biosafety in Microbiological and Biomedical Laboratories”, 1988. If you require further information, please contact your site Safety Officer or Technical Services.
Cambrex Bio Science Walkersville, Inc. www.cambrex.com/bioproducts biotechserv@cambrex.com
Orders: 800-638-8174 Technical Service: 800-521-0390 Copyright 2002 Cambrex Bio Science Walkersville, Inc.
302-774-4114anthony.r.farina@usa.dupont.com DUPONT REPORTS FIRST QUARTER 2003 EARNINGS • First quarter 2003 earnings, before special items and cumulative effect of changes in accounting principles, were $.61 per share compared with first quarter 2002 earnings of $.55, up 11 percent. • First quarter 2003 income before cumulative effect of changes in accounting principles was
CANADIAN PROSTATE CANCER SUPPORT GROUP Newmarket, Ontario Volume 14, Issue 4, December 15th, 2009 A support group that provides understanding, hope and information to prostate cancer patients and their families Make sure you come to our Christmas Meeting on December 10th, 2009 (note date change, it's the second Thursday this year). At the Newmarket Seniors Meeting Place,
Clonetics™ Myometrial Uterine Microvascular 
When placing an order or for technical service,
descriptions listed above. For a complete listing of all Clonetics products, refer to the Cambrex website
or the current Cambrex catalog. To obtain a
catalog, additional information or technical service
Product Warranty